Answers are grounded in this paper and cite their sources.
Relevance. The article presents the results of a comprehensive analysis of clinical, epidemiological, morphological, and anamnestic characteristics of 316 patients with non-small cell lung cancer (NSCLC), residents of the Khanty-Mansi Autonomous district – Yugra, in whom molecular genetic alterations were identified. Objective. To conduct a comprehensive analysis of clinical, morphological, demographic, and anamnestic (smoking history) parameters and duration of residence in the region in patients with NSCLC who have confirmed molecular genetic alterations, as well as to assess their differences from a reference group of patients in whom driver mutations have not been detected, in the territory of the Khanty-Mansi Autonomous district – Yugra. Materials and methods. The study included 316 cases of NSCLC registered at the oncology center based at the Surgut District Clinical Hospital during 2020–2023. All patients with morphologically verified NSCLC, regardless of stage and histological subtype, underwent testing of a panel of genetic markers including EGFR, ALK, ROS1, BRAF, ERBB2 (HER2), KRAS, MET, RET, NTRK1/2/3, and PD-L1 expression level was determined (<1%, 1–49%, ≥50%). Molecular genetic testing of surgical and biopsy material was performed in two consecutive stages using polymerase chain reaction (PCR) and nextgeneration sequencing (NGS) methods. Immunohistochemical analysis of PD-L1 expression was performed using validated test systems: clone 22C3 (DAKO) and clone SP263 (VENTANA). Morphological verification of the diagnosis was based on histopathological examination, and the extent of the process was assessed according to the 8th edition of the TNM system. For each patient, the following parameters were recorded: sex, age, smoking history, stage, tumor topography, histological subtype of NSCLC, PD-L1 expression, and continuous duration (years) of residence in KhMAO-Yugra before diagnosis. Depending on the presence or absence of molecular genetic alterations, two groups were formed: the main group (126 patients with driver mutations) and the comparison group (190 patients without them). To assess the prevalence of smoking in the general population of lung cancer patients (all histological subtypes) in KhMAO-Yugra, an additional retrospective analysis of the regional cancer registry database for the period from 2011 to 2022 (2018 cases) was performed. Medical records contained information on smoking status (current, former, or never smokers). These data were used for a comparative assessment of smoking frequency in the general cohort of lung cancer patients in the region and in the sample of patients who underwent molecular genetic testing. Statistical processing methods were used. Conclusions. The study showed that genetic aberrations are most common in adenocarcinoma (34% of cases), whereas in other histotypes their proportion is only 6%. In the mutation structure, alterations in EGFR (15%) and KRAS (14%) genes predominate; ALK rearrangements (5%), HER2 amplification (3%), ROS1 rearrangements (2%), and BRAF mutations (1%) are less frequently recorded. Significant associations were established: in non-smoking patients and in adenocarcinoma, the risk of detecting EGFR, KRAS mutations and ALK rearrangement is significantly higher, whereas long-term residence in the region (≥30 years) is associated with a lower probability of detecting EGFR mutations and ALK rearrangement. PD-L1 expression status did not affect the frequency of the studied driver mutations. The obtained data indicate regional features of the molecular profile of NSCLC in Yugra, which substantiates the need to adapt diagnostic algorithms and therapeutic approaches taking into account local clinical and epidemiological conditions to improve the effectiveness of drug provision and personalize treatment.
No takes yet. Share an insight, caveat, or question.
Mordovskiy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: